Patents by Inventor Matthew J. Wyvratt

Matthew J. Wyvratt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7834062
    Abstract: The present invention relates to Mannich base antimalarial aminoalkylphenol compounds and their use against protozoa of the genus Plasmodium, particularly emerging strains of drug-resistant Plasmodia. This invention further relates to compositions containing such compounds and a process for making the compounds. This and other aspects of the invention are realized upon review of the entire specification.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: November 16, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Conrad P. Dorn, Mary Ann Powles, Thomas F. Walsh, Matthew J. Wyvratt
  • Publication number: 20090298949
    Abstract: The present invention relates to Mannich base antimalarial aminoalkylphenol compounds and their use against protozoa of the genus Plasmodium, particularly emerging strains of drug-resistant Plasmodia. This invention further relates to compositions containing such compounds and a process for making the compounds. This and other aspects of the invention are realized upon review of the entire specification.
    Type: Application
    Filed: August 13, 2009
    Publication date: December 3, 2009
    Inventors: Conrad P. Dorn, Mary Ann Powles, Thomas F. Walsh, Matthew J. Wyvratt
  • Patent number: 7589127
    Abstract: The present invention relates to Mannich base antimalarial aminoalkylphenol compounds and their use against protozoa of the genus Plasmodium, particularly emerging strains of drug-resistant Plasmodia. This invention further relates to compositions containing such compounds and a process for making the compounds. This and other aspects of the invention are realized upon review of the entire specification.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: September 15, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Mary Ann Powles, Thomas F. Walsh, Matthew J. Wyvratt
  • Patent number: 7504501
    Abstract: Compounds described by the Formula (I): (I) or pharmaceutically acceptable salts, or N-oxides thereof. The compounds are useful for the treatment and prevention of protozoal diseases in mammals and birds. A method for controlling coccidiosis in poultry comprises administering an effective amount of the compound alone, or in combination with one or more anticoccidial agent(s). A composition for controlling coccidiosis in poultry comprises the compound alone, or in combination with one or more anticoccidial agent(s). Methods for the treatment and prevention of mammalian protozoal diseases, such as, for example, toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, and opportunistic infections comprise administering the compound alone, or in combination with one or more antiprotozoal agent(s).
    Type: Grant
    Filed: March 2, 2004
    Date of Patent: March 17, 2009
    Assignee: Merial Limited
    Inventors: Matthew J. Wyvratt, Tesfaye Biftu, Michael H. Fisher, Dennis M. Schmatz
  • Patent number: 7429590
    Abstract: Compounds described by the Formula (I) or (II): or pharmaceutically acceptable salts, or N-oxides thereof. The compounds are useful for the treatment and prevention of protozoal diseases in mammals and birds. A method for controlling coccidiosis in poultry comprises administering an effective amount of the compound alone, or in combination with one or more anticoccidieal agent(s). A composition for controlling coccidiosis in poultry comprises the compound alone, or in combination with one or more anticoccidial agent(s). Methods for the treatment and prevention of mammalian protozoal diseases, such as, for example, toxoplasmosis, malaria. African typanosomiasis, Chagas disease, and opportunistic infections comprise administering the compound alone, or in combination with one or more antiprotozoal agent(s).
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: September 30, 2008
    Assignee: Merck & Co. Inc.
    Inventors: Tesfaye Biftu, Matthew J. Wyvratt, Louis L. Zuegner, III, legal representative, Michael H. Fisher
  • Publication number: 20040266821
    Abstract: Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Application
    Filed: July 20, 2004
    Publication date: December 30, 2004
    Inventors: Feroze Ujjainwalla, Lin Chu, Mark T. Goulet, Bonnie Louridas, Matthew J. Wyvratt, Daniel Warner
  • Patent number: 6818658
    Abstract: Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: November 16, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Feroze Ujjainwalla, Lin Chu, Mark T. Goulet, Bonnie Louridas, Matthew J. Wyvratt, Daniel Warner
  • Publication number: 20030225060
    Abstract: Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Application
    Filed: February 3, 2003
    Publication date: December 4, 2003
    Inventors: Feroze Ujjainwalla, Lin Chu, Mark T. Goulet, Bonnie Louridas, Matthew J. Wyvratt, Daniel Warner
  • Patent number: 6586452
    Abstract: The present invention relates to novel nodulosporic acid derivatives, which are acaricidal, antiparasitic, insecticidal and anthelmintic agents.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Thomas Shih, Steven L. Colletti, Michael H. Fisher, Peter T. Meinke, Howard C. H. Kuo, Prasun K. Chakravarty, Matthew J. Wyvratt, Sriram Tyagarajan, Richard Berger
  • Publication number: 20030078369
    Abstract: Cyclic tetrapeptide compounds derived from apicidin therapeutically inhibit histone deacetylase activity, are represented by Formula I: 1
    Type: Application
    Filed: January 31, 2002
    Publication date: April 24, 2003
    Inventors: Peter T. Meinke, Dennis Schmatz, Robert W. Myers, Sandra J. Rattray, Steven L. Colletti, Matthew J. Wyvratt, Michael H. Fisher, Anne M. Gurnett
  • Patent number: 6528531
    Abstract: Trisubstituted pyrroles are antiprotozoal agents useful in the treatment and prevention of protozoal diseases in human and animals, including the control of coccidiosis in poultry.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: March 4, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Tesfaye Bitfu, Danqing D. Feng, Gui-Bai Liang, Mitree M. Ponpipom, Xiaoxia Qian, Michael H. Fisher, Matthew J. Wyvratt, Robert L. Bugianesi
  • Patent number: 6432980
    Abstract: Trisubstituted pyrroles are antiprotozoal agents useful in the treatment and prevention of protozoal diseases in human and animals, including the control of coccidiosis in poultry.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: August 13, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Tesfaye Biftu, Danqing D. Feng, Gui-Bai Liang, Mitree M. Ponpipom, Xiaoxia Qian, Narindar Girotra, Michael H. Fischer, Matthew J. Wyvratt
  • Patent number: 6399786
    Abstract: The present invention relates to novel nodulosporic acid derivatives, which are acaricidal, antiparasitic, insecticidal and anthelmintic agents.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: June 4, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Steven L. Colletti, Michael H. Fisher, Peter T. Meinke, Matthew J. Wyvratt
  • Publication number: 20020045653
    Abstract: The present invention relates to novel nodulosporic acid derivatives, which are acaricidal, antiparasitic, insecticidal and anthelmintic agents.
    Type: Application
    Filed: July 9, 2001
    Publication date: April 18, 2002
    Inventors: Thomas Shih, Steven L. Colletti, Michael H. Fisher, Peter T. Meinke, Dong Ok, Prasun K. Chakravarty, Matthew J. Wyvratt
  • Publication number: 20020045598
    Abstract: The present invention relates to novel nodulosporic acid derivatives, which are acaricidal, antiparasitic, insecticidal and anthelmintic agents.
    Type: Application
    Filed: July 9, 2001
    Publication date: April 18, 2002
    Inventors: Steven L. Colletti, Michael H. Fisher, Peter T. Meinke, Matthew J. Wyvratt
  • Patent number: 6291480
    Abstract: Trisubstituted pyrroles are antiprotozoal agents useful in the treatment and prevention of protozoal diseases in human and animals, including the control of coccidiosis in poultry.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: September 18, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Tesfaye Biftu, Danqing Dennis Feng, Gui-Bai Liang, Mitree M. Ponpipom, Xiaoxia Qian, Michael H. Fisher, Matthew J. Wyvratt
  • Patent number: 6211224
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: October 26, 1998
    Date of Patent: April 3, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Lin Chu, Mark Goulet, Thomas F. Walsh, Matthew J. Wyvratt, Stephanie L. Witkin
  • Patent number: 6211174
    Abstract: The present invention is directed to certain naphtho-fused lactams of the general structural formula: wherein and R1, R1a, R1b, R2a, R2b, R3a, R4, R5, R6, A, L, X, n, p and w are as defined herein. These compounds promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone.
    Type: Grant
    Filed: September 24, 1998
    Date of Patent: April 3, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Robert J. Devita, Matthew J. Wyvratt
  • Patent number: 6200957
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: July 14, 1998
    Date of Patent: March 13, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Wallace T. Ashton, Lin Chu, Michael H. Fisher, Peter Lin, Mitree M. Ponpipom, Matthew J. Wyvratt, Narindar N. Girotra, Jonathan Young
  • Patent number: 6197975
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: March 6, 2001
    Assignee: Merck & Co. , Inc.
    Inventors: Mark Goulet, Wallace T. Ashton, Lin Chu, Michael H. Fisher, Matthew J. Wyvratt